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Serum 14-3-3η level is associated with severity
and clinical outcomes of rheumatoid arthritis, and
its pretreatment level is predictive of DAS28
remission with tocilizumab
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Abstract
Introduction: Treat-to-target strategies to achieve low disease activity or clinical remission are key in the treatment
of rheumatoid arthritis (RA). 14-3-3η is a joint-derived biomarker that is expressed at significantly higher levels in
patients with RA than in healthy subjects, other autoimmune diseases, or viral and bacterial arthritides. In this study,
we sought to investigate the utility of pretreatment levels of 14-3-3η and serial measurement of 14-3-3η to inform
therapeutic outcomes.
Methods: Serum 14-3-3η levels were measured in 149 Japanese patients with RA before the initiation of therapy
and at 1-year follow-up. Patients were treated with either methotrexate (MTX), adalimumab (ADA), tocilizumab
(TCZ), or tofacitinib (TOF). 14-3-3η positivity was defined as ≥0.19 ng/ml and at two times and four times this cutoff.
In contingency analysis, we determined the association of 14-3-3η with disease severity. Wilcoxon matched-pairs
test was used to evaluate the significance of pre- to post-treatment changes. Mann–Whitney U test was performed
for differences between treatment response groups. Fisher’s exact test was used to assess associations of 14-3-3η
with a good response defined by European League Against Rheumatism criteria as well as remission defined by the
Disease activity Score in 28 joints with erythrocyte sedimentation rate (DAS28-ESR) and the Clinical Disease Activity
Index score.
Results: 14-3-3η-positive patients had more severe disease before the initiation of treatment. When combined with
C-reactive protein (CRP), 14-3-3η positivity added significantly and incrementally to the identification of patients with
high disease activity. 14-3-3η levels were significantly decreased at 1 year and were modifiable across all classes of
therapeutics. Patients who reverted to negative 14-3-3η levels had better clinical response than patients who remained
positive at 1 year or became positive. Pretreatment 14-3-3η levels informed 1-year DAS28-ESR remission in the
TCZ-treated group, in contrast to the ADA, MTX, or TOF groups, while no differences in pretreatment 14-3-3η
expression based on clinical response.
Conclusions: 14-3-3η is a modifiable marker in identifying patients with RA in a high disease state. Patients who
achieve a negative 14-3-3η status following 1-year of treatment do better clinically with pretreatment 14-3-3η
informing response to TCZ.
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Introduction
Because rheumatoid arthritis (RA) is a multifactorial
disease with a heterogeneous presentation and disease
course, identifying patients with aggressive early RA for
prompt and appropriate treatment is critical to minimize
irreversible joint destruction and disability [1]. If there is
intolerance or an inadequate response to initial therapy
with methotrexate (MTX) or another synthetic disease-
modifying antirheumatic drug (sDMARD), treatment
should be intensified to achieve remission or low disease
activity. Numerous biologic therapies targeting different
inflammatory pathways have been developed for the treat-
ment of RA, including those that target tumor necrosis
factor (infliximab, etanercept, adalimumab [ADA], certoli-
zumab, and golimumab), T-cell costimulation (abatacept),
B-cell depletion (rituximab), and the interleukin 6 receptor
(tocilizumab [TCZ]). Recently, small-molecule kinase in-
hibitors have been developed as therapeutics for RA, in-
cluding the Janus kinase inhibitor tofacitinib (TOF).
Importantly, even with early identification of RA and
prompt initiation of treatment, up to 70 % of patients do
not attain a satisfactory clinical response with therapy
switches within and between drug classes. This heteroge-
neous response to therapy provides strong evidence that
RA is likely caused by any one or a number of different
biochemical pathways acting alone and/or in concert,
resulting in the manifestation of common symptomology
and disease presentation. Notably, the pathologic factors
in early and late RA differ with respect to cytokine profiles
[2, 3]. These differences, together with heterogeneous
treatment response, indicate that there are fundamental
differences in the pathological processes based on the
stage of disease. This situation highlights the need for bio-
markers that can assist with personalizing treatment strat-
egies. Coupled with this information are the results of
phase III clinical trials demonstrating that the pathways
that drive the inflammatory process might be distinct
from those that ultimately lead to erosive disease [4–8].
14-3-3 proteins are an evolutionarily conserved family
of molecular chaperones that play a critical role in the
regulation of intracellular functions, including prolifera-
tion, differentiation, and metabolism, among other func-
tions. The 14-3-3 family consists of seven isoforms: alpha/
beta (α/β), epsilon (ε), gamma (γ), eta (η), tau (τ), zeta (ζ),
and sigma (σ). In 2007, Kilani et al. reported that, on the
basis of immunoblot analyses, 14-3-3η was found in sig-
nificantly higher amounts in the serum and synovial fluid
of patients with inflammatory arthritis compared with
healthy subjects [9]. In 2014, Maksymowych et al. re-
ported that levels of 14-3-3η, which were quantified using
a 14-3-3η enzyme-linked immunosorbent assay (ELISA),
were detectable at significantly higher levels in patients
with early and established RA than in healthy subjects and
patients with various autoimmune disorders and other
arthritides [10]. They also found, through receiver operat-
ing characteristic curve analysis, that levels ≥0.19 ng/ml
were highly discriminative for RA, with increasing 14-3-
3η positivity cutoffs providing greater discriminatory
power for the identification of RA. They also reported that
the 14-3-3η levels did not correlate with acute-phase reac-
tants such as C-reactive protein (CRP) and that common
factors present in the serum, including rheumatoid factor
(RF), did not interfere with the quantification of 14-3-3η
[10]. Other studies have further confirmed the differential
expression and specificity of 14-3-3η for RA [11–14].
In the present study, we evaluated 14-3-3η serum
expression levels in a cohort of Japanese patients with
established RA before the initiation of therapy and
following 1 year of treatment with commonly used
therapies, each with a differing mechanism of action,
including MTX, ADA, TCZ, and TOF, in daily clinical
practice. The relationship between disease severity,
outcome, and 14-3-3η expression was evaluated, along




Serum 14-3-3η was assessed in 149 Japanese patients with
established RA, classified according to the American
College of Rheumatology 1987 criteria [15] , before the
initiation of therapy with MTX, ADA, TCZ, or TOF and
following 1 year of treatment in daily clinical practice. The
vast majority of patients in this study were women (86 %),
and the cohort had a mean (standard deviation) age of 57
(15) years and a median (interquartile range [IQR]) disease
duration of 51 (9–150) weeks. A total of 23 patients
received MTX, 49 received ADA, 50 received TCZ, and
27 received TOF. Clinical examinations by a certified
rheumatologist were completed for all patients before ini-
tiation of therapy and after 1 year of treatment. Assess-
ments included Disease Activity Score in 28 joints with
erythrocyte sedimentation rate (DAS28-ESR), Clinical Dis-
ease Activity Index (CDAI), Simple Disease Activity Index
(SDAI), 28-joint tender joint count (TJC28), 28-joint swol-
len joint count (SJC28), Sharp/van der Heijde score (SHS),
joint space narrowing (JSN), and erosion score. Serological
assessments included erythrocyte sedimentation rate
(ESR), CRP, RF, and anticitrullinated protein antibodies
(ACPA). The study was performed in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all study participants, and ethical approval
was received from the University of Occupational and
Environmental Health, Japan.
Serum 14-3-3η measurements
Serum 14-3-3η levels were measured using a quantitative
14-3-3η ELISA kit (Augurex Life Sciences Corporation,
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Vancouver, BC, Canada). A 14-3-3η cutoff of ≥0.19 ng/ml—
the positivity cutoff established by Maksymowych et al.
[10]—was used to define 14-3-3η positivity. Two additional
14-3-3η positivity cutoffs also described by Maksymowych
et al. [10] were used: one at twice the positivity cutoff
(≥0.40 ng/ml) and the other at four times the positivity cut-
off (≥0.80 ng/ml).
Statistical analyses
The Mann–Whitney U test was used to assess clinical
and serological differences between treatment groups at
initiation and after 1 year of therapy. The relationship of
14-3-3η to clinical measures was assessed using Spearman’s
rank correlation coefficient. Contingency analysis pro-
vided the strength of association of 14-3-3η status with
DAS28-ESR, CDAI, and SDAI categorization (i.e., remis-
sion or low, moderate, or high disease state). To assess the
complementarity between 14-3-3η and CRP in identifying
patients in a CDAI-defined high disease state, CRP posi-
tivity was defined as ≥10 mg/L. Patients were categorized
as being either negative for both markers, positive for any
one of the two markers, or positive for both markers. The
Wilcoxon matched-pairs signed-rank test was used to
evaluate the significance of pre- to posttreatment changes
in 14-3-3η levels within therapy groups. An unpaired t test
assuming equal variances was used to compare differences
between groups with fewer than 10 patients. Fisher’s exact
test was employed to determine the association between
positivity of 14-3-3η and a good response as defined by
European League Against Rheumatism (EULAR) criteria
[16] or remission as defined by DAS28-ESR. DAS28-ESR
and CDAI remission were defined as scores <2.6 and ≤2.8,
respectively. All statistical analyses were completed with
Prism 6 (GraphPad Software, La Jolla, CA, USA) or JMP
11 (SAS Institute, Cary, NC, USA) software. A p value
<0.05 denoted statistical significance.
Results
Positivity of 14-3-3η informs a worse disease state
Before the initiation of therapy, 110 patients (74 %) were
14-3-3η-positive based on the 14-3-3η positivity cutoff
of ≥0.19 ng/ml (Table 1). 14-3-3η-positive patients had
significantly higher median (IQR) DAS28-ESR, CDAI,
SDAI, TJC28, and SJC28 scores at initiation than pa-
tients who were 14-3-3η-negative. 14-3-3η-positive pa-
tients also had significantly higher ESR, ACPA, and RF
levels.
Spearman’s correlation analysis revealed that titers of
14-3-3η at therapy initiation correlated modestly with
DAS28-ESR, CDAI, SDAI, JSN, TJC28, SJC28, CRP, and
ESR values (Table 2). Contingency analysis revealed a
strong and significant association at initiation between
patients in higher 14-3-3η cutoff categories with moder-
ate and/or high disease severity across the three different
indices: DAS28-ESR, CDAI, and SDAI (Table 3). Because
14-3-3η had a modest correlation with CRP, the comple-
mentarity of these two markers in identifying patients
with a CDAI-defined high disease status was assessed.
As depicted in Table 3, using the ≥0.80 ng/ml cutpoint
for positivity, 14-3-3η delivered a likelihood ratio (LR) of
14.0. Positivity for CRP based on ≥10 mg/L delivered a
significant and strong LR of 20.5 (p < 0.0001). As illus-
trated in Fig. 1a and described herein, positivity for both
14-3-3η and CRP identified a significantly higher pro-
portion of patients who are in a CDAI-defined high dis-
ease state than those who are positive for any one of the
two markers or negative for both. The LR for CRP in-
creased from 20.5 to 37.6 9p < 0.0001) when both
markers were combined. This complementarity with
CRP was also observed at the 0.19 ng/ml positivity cutoff
for 14-3-3η, with the combined LR being 24.3 (p <
0.0001).
Levels of 14-3-3η are modifiable overtime
After 1 year of treatment, 97 patients (65 %) were 14-3-
3η-positive. The data in Table 4 and Fig. 1b demonstrate
that pretreatment 14-3-3η serum levels were signifi-
cantly higher than 1-year levels across the whole group
(p < 0.0001). As illustrated in Fig. 1c, the levels of 14-3-
3η either increased, decreased, or stayed the same over
time. Of the 110 patients who were positive for 14-3-3η
before the initiation of treatment, 18 reverted or became
negative (BN) based on the ≥0.19 ng/ml positivity cutoff,
whereas 92 remained positive (RP). Of the 39 patients
who were negative at treatment initiation, 5 converted at
1 year or became positive (BP) based on the 0.19 ng/ml
positivity cutoff, whereas 34 remained negative (RN).
The Kruskal-Wallis test revealed a significant differ-
ence in DAS28-ESR at 1 year between the four 14-3-3η
modifiability groups (stayed negative, BN, stayed positive
[SP], BP) (p = 0.014). DAS28-ESR levels were not signifi-
cantly different among the four different groups before
the initiation of treatment. By post hoc Dunn’s testing, a
significant difference (p ≤ 0.05) in median DAS28-ESR
levels was demonstrated between BN patients (2.01;
1.60–2.80) and SP patients (5.27; 4.57–7.34) (Fig. 1d).
The Mann–Whitney U test further highlighted this dif-
ference (p = 0.004). To assess whether a difference in 1-
year DAS28-ESR existed between the BP group versus
the BN group, an unpaired t test assuming equal vari-
ances revealed that mean DAS28-ESR 1-year levels were
significantly lower in the 18 BN patients than in the 5
BP patients (2.09 ± 0.18 vs 3.09 ± 0.52; p = 0.033).
Relationship of 14-3-3η to therapy
As shown in Table 4, the levels of 14-3-3η before the
initiation of therapy and the posttreatment levels at
1 year were significantly different across all four classes
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of therapy. Response rates across the whole cohort based
on DAS28-ESR-defined remission and a EULAR-defined
good response were 55 % and 71 %, respectively. When
we examined the differential expression of 14-3-3η by
therapy response, 14-3-3η levels before the initiation of
therapy emerged as significantly lower in the TCZ
treated group that achieved DAS28-ESR remission. This
finding was in contrast to those in the ADA, MTX, and
TOF treated groups (Table 5), where no difference was
seen in the levels of the 14-3-3η before the initiation of
treatment. Interestingly, no significant differences in pre-
treatment CRP levels were observed across the whole
cohort and within the different therapy groups. Similar
to 14-3-3η, CRP levels at 1 year were significantly lower
in the TCZ group that achieved a DAS28 ESR remission.
For a EULAR-defined good response, whereas 14-3-3η
baseline levels in these groups appeared different, the
nonresponder subgroup was too small to return a sig-
nificant difference.
Fisher’s exact test revealed that pretreatment 14-3-3η
at all positivity cutpoints was associated with the
achievement of DAS28-ESR remission in TCZ-treated
patients with pretreatment levels of ≤0.40 ng/ml, deliver-
ing the strongest LR of 15.67 (p = 0.0001). As DAS28-
ESR levels at initiation were significantly lower in
DAS28-ESR remitters in the TCZ group (Table 5), con-
trolling for DAS28-ESR in a multivariable regression
model demonstrated that a 14-3-3η level ≤0.40 ng/ml
Table 1 Pretreatment patient characteristics
Variable Entire cohort 14-3-3η-negative 14-3-3η-positive p Value
Number of patients 149 39 110
Categorical variables
Sex (% female) 128 (86 %) 34 (87 %) 94 (85 %) 0.7937
RF status (% positive) 126 (85 %) 21 (54 %) 105(95 %) <0.0001
ACPA status (% positive) 97 (65 %) 20 (67 %)a 78 (98 %)b <0.0001
14-3-3η status (% positive) 110 (74 %) 0 (0 %) 110 (100 %) <0.0001
Concomitant use of MTX (%) 117 (79 %) 34 (87 %) 83 (76 %) 0.1733
Continuous variables
Age (yr)c 57.3 (14.7) 54.6 (16.1) 58.2 (14.1) 0.1924
RA duration (mo) 51 (9–150) 34 (9–132) 55 (11–159) 0.3791
MTX dose (mg/wk) 8.0 (5.0–10.0) 8.0 (6.0–10.0) 8.0 (1.5–10.0) 0.456
DAS28-ESR 5.35(4.40–6.45) 4.77 (4.10–5.86) 5.62 (4.64–6.57) 0.0101
HAQd 1.07 (0.60–1.88) 1.00 (0.47–1.88) 1.13 (0.63–1.85) 0.7328
CDAI 22.2 (14.0–33.5) 16.0 (11.5–27.0) 24.7 (16.2–36.3) 0.015
SDAI 24.3 (14.3–37.4) 18.8 (11.7–32.7) 26.8 (16.7–38.6) 0.0238
TJC28 7.0 (4.0–13.5) 5.0 (2.0–12.0) 7.0 (4.0–14.0) 0.0327
SJC28 6.0 (2.0–9.0) 4.0 (2.0–9.0) 6.5 (2.8–10.0) 0.0466
SHS 26.5 (4.5–90.8) 14.0 (3.0–88.5) 31.3 (6.9–99.9) 0.1185
JSN scoree 18.0 (3.0–45.5) 9.0 (1.5–42.5) 19.8 (4.1–47.4)f 0.11
Erosion scoree 10.5 (2.0–45.5) 5.0 (2.0–40.5) 12.8 (2.5–53.0)f 0.108
ESR 44.0 (21.5–72.5) 35.0 (17.0–58.0) 47.5 (22.8–80.0) 0.0482
CRP (mg/dl) 0.83(0.23–3.13) 0.69 (0.20–2.70) 0.99 (0.26–3.44) 0.3769
RF 60.4 (27.4–171.8) 15.5 (5.8–43.2) 84.5 (41.9–242.1) <0.0001
ACPA 100.0 (27.4–100) 16.9 (1.9–100)a 100.0 (52.0–100)b 0.0002
14-3-3η (ng/ml) 0.70 (0.17–5.96) 0.10 (0.04–0.13) 1.70 (0.49–11.0) <0.0001
Abbreviations: ACPA anticyclic citrullinated antibodies, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-ESR Disease Activity Score in 28 joints with
erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, JSN joint space narrowing, MTX methotrexate, RF
rheumatoid factor, RA rheumatoid arthritis, SDAI Simple Disease Activity Index, SHS Sharp/van der Heijde score, SJC28 28-joint swollen joint count, TJC28 28-joint
tender joint count
All p values were generated based on Mann–Whitney analysis, with the exception of age, which was generated using paired t tests.
aData were available for 30 patients
bACPA values were available for 80 patients
cAge is presented as the mean (standard deviation). All other variables are presented as the median (interquartile range).
dHAQ scores were available for 146 patients
eJSN and erosion scores were available for 147 patients
fJSN and erosion scores were available for 108 patients
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was an independent predictor of DAS28-ESR remission
in TCZ-treated patients (LR = 10.24, p = 0.0014).
Because 14-3-3η and CRP levels were significantly
lower at 1 year in DAS28-ESR remitters treated with
TCZ, Fisher’s exact test was performed to assess the as-
sociation of both of these markers with DAS28-ESR-
and CDAI-defined remission. In both instances, positivity
of 14-3-3η at 1 year, based on the cutpoint of 0.19 ng/ml,
was associated with clinical remission (DAS28-ESR-
defined remission LR = 6.96, p = 0.01; CDAI-defined re-
mission LR = 7.14, p = 0.01), whereas CRP positivity de-
fined as ≥10 mg/L was not.
Discussion
In this cohort of Japanese patients with established RA,
the results corroborate previously published findings
that 14-3-3η-positive status corresponds with higher dis-
ease severity. We report, for the first time to our know-
ledge, that a positive status and higher levels of 14-3-3η
based on different positivity cutpoints inform “moderate”
and/or “high disease” activity states based on DAS28-ESR,
CDAI, and SDAI scores. We also corroborate previously
published findings that 14-3-3η has a modest correlation
with the acute-phase reactants CRP and ESR [10, 17] and
illustrate for the first time that the addition of 14-3-3η to
CRP is significantly useful in identifying patients in a
CDAI-defined high disease state. In this regard, the LR for
moderate to high disease categorization based on CDAI
increased from 20.5 to 37.6 when 14-3-3η was added to
CRP. Although in this study we specifically evaluated
14-3-3η in RA, in other diseases it has been reported
that elevated expression of other 14-3-3 isoforms is as-
sociated with more severe disease or worse outcomes,
including but not limited to cancer and Creutzfeldt-
Jakob disease [18–26].
Although higher expression of 14-3-3 proteins has
been noted to be associated with less favorable outcomes
across different pathologies, whether these proteins are
causal or exist as a consequence of disease is yet to be
fully elucidated. Of interest, Maksymowych and col-
leagues reported, on the basis of their in vitro and ex
vivo experiments, that extracellular 14-3-3η, in a
Table 3 Pretreatment 14-3-3η positivity and association with disease state
DAS28-ESR categorya SDAI category CDAI category
Cutpoint ≥0.19 ng/ml ≥0.40 ng/ml ≥0.80 ng/ml ≥0.19 ng/ml ≥0.40 ng/ml ≥0.80 ng/ml ≥0.19 ng/ml ≥0.40 ng/ml ≥0.80 ng/ml
Pretreatment LR 10.6 16.3 25.2 3.7 9.7 16.3 6.2 8.8 14.0
p-value 0.0011 <0.0001 <0.0001 0.16 (ns) 0.0077 0.0003 0.045 0.012 0.0009
1 yr LR 10.1 5.1 2.6 2.2 1 1 2.2 1.1 0.8
p-value 0.0064 0.079 (ns) 0.27 (ns) 0.34 (ns) 0.61 (ns) 0.61 (ns) 0.34 (ns) 0.57 (ns) 0.69 (ns)
Abbreviations: DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, SDAI Simple Disease Activity Index, CDAI Clinical Disease Activity
Index, LR likelihood ratio, ns not significant
aCalculated based on 145 patients for pretreatment and 146 for 1 yr
Table 2 Spearman’s correlation coefficients of pretreatment clinical variables with 14-3-3η




HAQ 0.59a 0.54a 0.53a
SHS 0.34a 0.28b 0.27b 0.43a
JSN score 0.33a 0.28b 0.27b 0.41a 0.98a
Erosion score 0.32a 0.24b 0.23b 0.43a 0.97a 0.91a
TJC28 0.80a 0.86a 0.89a 0.45a 0.19c 0.19c 0.16
SJC28 0.73a 0.84a 0.84a 0.33a 0.35a 0.33a 0.28b 0.69a
14-3-3η 0.29a 0.24b 0.25d 0.05 0.16 0.18c 0.16 0.21c 0.26b
CRP 0.58a 0.49a 0.36a 0.34a 0.32a 0.32a 0.32a 0.22b 0.29a 0.20c
ESR 0.64a 0.37a 0.29a 0.34a 0.33a 0.32a 0.32a 0.18c 0.29b 0.27b 0.75 a
Abbreviations: CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, ESR
erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, JSN joint space narrowing, SDAI Simple Disease Activity Index, SHS Sharp/van der Heijde









Fig. 1 (See legend on next page.)
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concentration-dependent manner using clinically rele-
vant levels detectable in the serum of patients with RA,
is capable of inducing both proinflammatory cytokines
and chemokines and those factors that are directly in-
volved in the degradation of cartilage and bone [17, 27].
More recently, they also reported that targeting 14-3-3η
using an antibody-based approach in the collagen-
induced arthritis mouse model delayed the onset of dis-
ease and reduced the overall disease severity [28].
In the present study, 14-3-3η levels at 1 year were also
determined to be significantly lower across the whole
cohort, as well as within each treatment group, when
compared with the corresponding level before the initi-
ation of treatment. Serial changes in 14-3-3η reflect the
dynamic state of this marker wherein its modifiability
over time, as well as its association with therapy re-
sponse, is in clear contrast to RA biomarkers such as RF
and/or ACPA, which are relatively undynamic with re-
gard to treatment response [29]. We also report that re-
version to a normal 14-3-3η state (i.e., ≤0.19 ng/ml) was
associated with better clinical outcomes. In particular,
patients who were 14-3-3η-positive at therapy initiation
and reverted to a negative status at the 1-year follow-up
had significantly lower DAS28-ESR scores than RP or
BP patients. This association with disease activity is
further corroborated by the fact that 88 % of 14-3-3η-
negative patients at 1 year were in remission or in a low
disease activity state compared with 66 % of 14-3-3η-
positive patients. On the basis of these data, 14-3-3η
may have utility as a marker of clinical response, and the
impact of targeting a normal 14-3-3η level as part of a
patient management strategy needs to be evaluated
prospectively.
Because the ultimate goal for RA patient management
is to achieve full clinical remission and halt radiographic
damage and/or progression, more precise patient man-
agement through the use of markers such as 14-3-3η
may assist in implementing treat-to-target strategies.
Smolen et al. put forth a set of recommendations in
which they stated that, with long-standing disease, as
was the case for most patients in the present study,
achieving low disease activity in those who are refractory
to therapy is an important step in disease management,
whereas in early disease, low disease activity should be
considered a step toward clinical remission [30]. In the
present study, we demonstrate that 14-3-3η levels at
1 year, across the whole cohort, were significantly lower
in those who achieved a EULAR-defined good response.
When evaluated in relation to the type of therapy ad-
ministered, lower 14-3-3η pretreatment level was deter-
mined to be an independent predictor of DAS28-defined
remission in patients who were treated with TCZ but
not with any of the other classes of therapy. Moreover,
1-year 14-3-3η levels were associated with DAS28-ESR-
and CDAI-defined remission. It is noteworthy that CRP
levels at therapy initiation were not an independent pre-
dictor of DAS28-ESR-defined remission, nor were the
levels at 1 year informative of DAS28-ESR- or CDAI-
defined remission. On the basis of these findings, further
studies in larger cohorts are warranted to examine the
utility of 14-3-3η in predicting and monitoring response
outcomes across different classes of therapy, more spe-
cifically in patients with early RA.
As this was an observational study, it has several limi-
tations. First, the pretreatment characteristics of the
MTX group were quite different from the other groups,
with the patients being recruited in a consecutive man-
ner. Second, the majority of patients in the ADA group
and the TCZ group, as well as all patients in the TOF
group, had histories of inadequate response to MTX.
(See figure on previous page.)
Fig. 1 14-3-3η expression. a Clinical Disease Activity Index (CDAI)-defined disease states. The bar chart illustrates the relationship between 14-3-3η
and/or C-reactive protein positivity and CDAI-defined disease status, b Changes between pre- and posttreatment. The box plot shows the change
median levels of 14-3-3η over time, c Pairing by patient. The graph illustrates individual patients’ changes between pretreatment and posttreatment
14-3-3η serum levels. d Disease Activity Score in 28 joints with erythrocyte sedimentation rate (DAS28-ESR) based on changes in 14-3-3η expression.
The box plot illustrates changes in median DAS28-ESR expression as 14-3-3η positivity changes over time. *Significance values were calculated using
Dunn’s posttest
Table 4 14-3-3η levels by therapy group at baseline and after 1 year of therapy
Group Sample size Pretreatment 14-3-3η 14-3-3η at 1 yr p Value
Whole cohort 149 0.70 (0.17–5.96) 0.37 (0.11–1.82) <0.0001
Adalimumab 49 0.62 (0.16–4.66) 0.38 (0.13–1.40) <0.0001
Methotrexate 23 0.67 (0.17–1.89) 0.33 (0.11–1.44) 0.0101
Tocilizumab 50 0.43 (0.15–8.40) 0.27 (0.10–2.58) 0.0007
Tofacitinib 27 1.30 (0.21–9.46) 1.26 (0.11–3.07) 0.013
Median (interquartile range) 14-3-3η serum titers at baseline and at 1 yr are compared with the whole cohort and each therapy group. Corresponding Wilcoxon
matched-pairs signed-rank test values were calculated
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Table 5 Clinical response after 1 year, by therapy
All therapies ADA MTX TCZ TOF
Patients (n) 149 49 23 50 27
Pretreatment DAS28-ESR 5.35 (4.40–6.45) 5.33 (4.34–627) 4.23 (3.84–5.12) 5.43 (4.57–6.51) 6.34 (5.74–7.11)
DAS28-defined remission Y N Y N Y N Y N Y N
Patients (n) 82 67 26 23 15 8 30 20 11 16
Pretreatment DAS28-ESR 5.00 (4.09–6.13)a 5.85 (4.90–6.77) 5.30 (4.06–5.83) 5.67 (4.82–6.77) 4.11 (3.75–4.43) 4.78 (4.24–5.27) 4.80 (4.23–6.27)b 6.02 (5.30–7.44) 6.60 (5.60–7.11) 6.28 (5.78–7.09)
Response rate 55 % 53 % 65 % 60 % 41 %
Pretreatment 14-3-3η (ng/ml) 0.50 (0.16–4.95) 1.05 (0.19–7.75) 1.16 (0.20–9.06) 0.47 (0.13–2.14) 0.70 (0.17–1.89) 0.42 (0.16–14.55) 0.23 (0.09–3.03)b 4.02 (0.46–19.77) 1.05 (0.30–9.46) 1.56 (0.20–11.58)
1-yr 14-3-3η (ng/ml) 0.33 (0.10–1.45) 0.62 (0.14–3.11) 0.75 (0.14–2.96) 0.30 (0.13–1.17) 0.37 (0.11–0.62) 0.28 (0.07–18.33) 0.13 (0.08–0.75)b 1.52 (0.28–5.57) 1.24 (0.11–1.85) 1.27 (0.11–5.08)
Pretreatment CRP (mg/ml) 0.73 (0.15–3.12) 1.14 (0.26–3.40) 0.62 (0.14–5.01) 1.14 (0.40–5.32) 0.36 (0.06–0.83) 0.18 (0.08–1.34) 0.92 (0.14–2.18) 2.67 (0.40–3.50) 2.97 (0.56–5.22) 1.04 (0.33–2.98)
1-yr CRP (mg/ml) 0.03 (0.01–0.09)b 0.09 (0.02–0.37) 0.04 (0.02–0.13)a 0.14 (0.07–1.22) 0.05 (0.02–0.13) 0.12 (0.03–0.31) 0.01 (0.00–0.030)c 0.03 (0.01–0.18) 0.03 (0.02–0.16) 0.04 (0.03–0.28)
EULAR-defined good response Y N Y N Y N Y N Y N
Patients (n) 101 43 30 19 16 4 40 8 15 12
Pretreatment DAS28-ESR 5.32 (4.33–6.45) 5.77 (4.70–6.55) 5.33 (4.33–6.03) 5.32 (4.32–6.77) 4.21 (3.83–5.03) 4.42 (3.32–5.37) 5.02 (4.37–6.61) 5.75 (4.83–6.02) 6.60 (5.74–7.25) 6.10 (5.53–6.60)
Response rate 70 % 61 % 80 % 83 % 56 %
Pretreatment 14-3-3η (ng/ml) 0.62 (0.16–5.02) 1.48 (0.20–12.72) 0.61 (0.12–3.61) 0.70 (0.24–5.84) 0.65 (0.12–1.03) 1.05 (0.20–14.82) 0.37 (0.16–7.33) 10.34 (0.19–>20) 1.05 (0.30–8.16) 1.56 (0.20–14.02)
1-yr 14-3-3η (ng/ml) 0.28 (0.10–1.51)b 0.80 (0.27–5.99) 0.45 (0.11–1.45) 0.36 (0.22–1.41) 0.30 (0.10–0.47)c 7.39 (0.53–>18.33) 0.18 (0.08–2.02)b 3.42 (0.39–>20) 1.24 (0.11–1.85) 1.35 (0.19–9.06)
Pretreatment CRP (mg/ml) 0.96 (0.21 – 3.35) 0.64 (0.23 –3.08) 0.80 (0.27 – 5.33) 0.68 (0.30 – 4.20) 0.16 (0.05–0.80) 0.33 (0.10–1.34) 1.10 (0.20–3.11) 0.60 (0.16–2.99) 2.18 (0.77–4.28) 1.04 (0.26–3.58)
1-yr CRP (mg/ml) 0.03 (0.01 – 0.12)c 0.11 (0.03 – 0.50) 0.05 (0.02 – 0.14)a 0.13 (0.07 – 1.50) 0.04 (0.02–0.24) 0.13 (0.03–0.22) 0.01 (0.00–0.05)a 0.06 (0.02–1.36) 0.03 (0.02–0.16) 0.07 (0.02–0.28)
Abbreviations: ADA adalimumab, CRP C-reactive protein; DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, EULAR European League Against Rheumatism,MTXmethotrexate, TCZ tocilizumab, TOF tofacitinib

















Thus, this reflects the shorter symptom duration and
lower pretreatment DAS28-ESR in the MTX group. Last,
it would have been ideal if the sample sizes and response
rates across the different treatment groups had been
balanced.
Conclusions
Positivity of 14-3-3η is associated with more severe dis-
ease and combines with CRP to identify patients at
higher risk. Serial decreases in 14-3-3η levels in response
to therapy are associated with better clinical outcomes,
whereas increases or sustained levels of the marker are
associated with a worse prognosis. Pretreatment 14-3-3η
level was an independent predictor of DAS28-ESR-
defined remission in patients treated with TCZ.
Abbreviations
ACPA: anticitrullinated protein antibodies; ADA: adalimumab; BN: became
negative; BP: became positive; CDAI: Clinical Disease Activity Index; CRP: C-reactive
protein; DAS28: Disease Activity Score in 28 joints; ELISA: enzyme-linked
immunosorbent assay; ESR: erythrocyte sedimentation rate; EULAR: European
League Against Rheumatism; HAQ: Health Assessment Questionnaire;
IQR: interquartile range; JSN: joint space narrowing; LR: likelihood ratio;
MTX: methotrexate; RA: rheumatoid arthritis; RF: rheumatoid factor; RP: remained
positive; SD: standard deviation; SDAI: Simple Disease Activity Index;
sDMARD: synthetic disease-modifying antirheumatic drug; SHS: Sharp/van der
Heijde score; SJC28: 28-joint swollen joint count; SP: stayed positive;
TCZ: tocilizumab; TJC28: 28-joint tender joint count; TOF: tofacitinib.
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